imatinib mesylate
information and resources from the National Cancer Institute
NCI Thesaurus | imatinib mesylate
The mesylate salt of an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that harbor the Philadelphia chromosome. Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST). This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins. NCI Thesaurus | imatinib mesylate
The mesylate salt of an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that harbor the Philadelphia chromosome. Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST). This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.
Gleevec
Accel. Approv. (clinical benefit not established) Initial therapy of chronic myelogenous leukemia
Novartis May 10 2001
Gleevec
Accel. Approv. (clinical benefit not established) Initial treatment of newly diagnosed Ph+ chronic myelogenous leukemia (CML).
Novartis Dec 20 2002
Gleevec
Accel. Approv. (clinical benefit not established) metastatic or unresectable malignant gastrointestinal stromal tumors
Novartis Feb 01 2002
|
|
|
|
news articles
FDA Orphan Drug Approvals: Ceflatonin, Valortim, TQ-1018 Mar 31, 2006
Medscape (subscription) In a single-agent study of 9 patients with accelerated-phase CML that had become resistant to imatinib mesylate, 80% of patients returned to chronic-phase CML ...
Recent findings in leukemia described Mar 30, 2006
Therapeutics Daily (subscription) (press release), ..."Although the Abelson (Abl) tyrosine kinase inhibitor imatinib mesylate has improved the treatment of breakpoint cluster region-Abl (Bcr-Abl)-positive leukemia ...
Surgery for Residual GIST May Improve Outcomes Mar 30, 2006
Cancer Consultants (press release), ...with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) that respond to treatment with Gleevec® (imatinib mesylate) may benefit ...
Patent Application For AIDS Drug Opposed For First Time in India Mar 30, 2006
Doctors Without Borders, Indian cancer patients and generic drug manufacturers recently opposed a Novartis patent application for Gleevec (Imatinib Mesylate), an anti-cancer drug, on ...
High-Dose Gleevec® and Low-Dose Chemotherapy Effective for ... Mar 17, 2006
Cancer Consultants (press release), According to an article recently published in the journal Leukemia, high doses of Gleevec® (imatinib mesylate) and low-dose chemotherapy appears to be an ...
Gleevec® Produces a Treatment Response in Some Patients with ... Mar 23, 2006
Cancer Consultants (press release), According to a phase II clinical trial published in the Journal of Clinical Oncology, treatment with Gleevec® (imatinib mesylate) reduced detectable disease ...
Research and Markets: The FDA is Encouraging the Use of Biomarkers ... Mar 22, 2006
PharmaLive.com (press release), Several companion diagnostics for molecularly targeted oncology drugs, including trastuzumab (Genentech's Herceptin), imatinib mesylate (Novartis's Gleevec ...
Kidney Cancer Patients are Unlikely to Respond to Potential ... Mar 7, 2006
eMaxHealth.com, Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs ...
New Hope for Stomach Cancer Mar 1, 2006
ABC30.com, For a few years, the drug Gleevec (imatinib mesylate, STI571, STI-571, or STI 571) kept Russo's cancer in check. But like many patients, he became resistant. ...
Pharma cos fight pitched battle on patent turf Mar 7, 2006
Hindu Business Line, Only recently, the Indian Patent office rejected Novartis's claim for a patent on imatinib mesylate, a cancer drug sold by it under the brand name Gleevec. ...
New Therapies Target Cancer Mar 7, 2006
Drug Discovery & Development (subscription), In 2001, Gleevec (imatinib mesylate), made by Novartis AG, Basel, Switzerland, became the first approved kinase inhibitor for cancer, specifically chronic ...
Cell Genesys to Present Data From Two GVAX(R) Cancer Immunotherapy ... Mar 13, 2006
PR Newswire (press release), ...for leukemia in a Phase 2 clinical trial in patients with chronic myelogenous leukemia (CML) who have been treated with Gleevec(R) (imatinib mesylate) for at ...
Conor Medsystems Licenses Compound from Novartis for Development ... Mar 16, 2006
PharmaLive.com (press release), In March of 2005, Conor and Novartis announced an agreement to evaluate three Novartis pharmaceutical agents – imatinib mesylate, pimecrolimus and a pre ...
Gleevec® plus Hydroxyurea Beneficial for Some Patients with ... Dec 20, 2005
Cancer Consultants (press release), ...to a recent article published in the Journal of Clinical Oncology, the treatment combination consisting of Gleevec (imatinib mesylate) plus hydroxyurea ...
More Than 90% of Patients Taking Gleevec(R) for a Form of Chronic ... Dec 12, 2005
Yahoo! News (press release) 12 /PRNewswire/ -- More than 90% of patients with a form of chronic myeloid leukemia (CML) who are taking Gleevec® (imatinib mesylate)* tablets in a landmark ...
Discoveries Reveal Gene Mutation That Causes Blood Disorders Dec 11, 2005
PR Newswire (press release), ...many cancers, including chronic myelogenous leukemia (CML), the treatment of which was revolutionized with the discovery of imatinib mesylate (commonly known ...
Dasatinib Shown Effective for Treating Two Forms of Leukemia ... Dec 12, 2005
DG News Imatinib mesylate (Gleevec) resistance in CML and Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (Ph + ALL) is frequently associated with ...
Dacogen(TM) (Decitabine) Injection Data Presented at American ... Dec 12, 2005
Genetic Engineering News, Poster Session 250-I Saturday, December 10, 2005, 9:15 AM Abstract Number: 1099 Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients ...
AMN107 May Benefit Leukemia Patients Resistant to Gleevec ... Dec 12, 2005
DG News December 12, 2005 -- The targeted agent AMN107 may be beneficial for some leukemia patients who are resistant to Gleevec (imatinib mesylate), according to a ...
CML Survival with Gleevec Remains High Dec 12, 2005
MedPage Today, 12 - More than 90% of patients taking Gleevec (imatinib mesylate) for chronic myeloid leukemia (CML) are alive and have not progressed to advanced disease more ...
Glivec Seeking to Become First Targeted Treatment for Adult ... Dec 13, 2005
PharmaLive.com (press release), December 13, 2005 – Novartis has submitted a marketing authorization application for Glivec® (imatinib) Known as Gleevec® (imatinib mesylate) tablets in ...
Annual Meeting of the American Society of Hematology Highlights ... Dec 6, 2005
PR Newswire (press release), ...abstracts: Saturday, December 10, 2005: Abstract 1097 Title: "Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients ...
Cell Genesys Reports Positive Results From Phase 2 Trial of GVAX(R ... Dec 12, 2005
PR Newswire (press release), Nineteen CML patients with molecular evidence of persistent leukemia despite more than one year of Gleevec(R) (imatinib mesylate) therapy were treated with ...
ChemGenex Reports Compelling Phase 2 Data Published In Leading ... Dec 11, 2005
PR Newswire (press release), ...entitled "Subcutaneous (SC) Homoharringtonine (HHT) for Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase after Imatinib Mesylate Failure." (2 ...
Genzyme Launches Colorectal Cancer Test to Determine Appropriate ... Dec 6, 2005
Yahoo! News (press release) ...worldwide diagnostic rights to its discovery of gene mutations believed to be associated with resistance to Gleevec® (imatinib mesylate), the current first ...
Results Encouraging with Interferon Alpha Plus Iressa (Gefitinib) ... Nov 22, 2005
DG News PHILADELPHIA, PA -- November 22, 2005 -- In a phase 2 study of interferon alpha (IFN) plus either Gleevec (imatinib mesylate) or Iressa (gefitinib) in patients ...
Annual Meeting of the American Society of Hematology Highlights ... Dec 6, 2005
PR Newswire (press release), Title: "Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML ...
Surprise benefit of unexpected diagnosis Nov 23, 2005
CNN ...on an article about young women diagnosed with CML who were experiencing remarkable remissions through treatment with the cancer pill Gleevec (imatinib mesylate ...
HEALTH BRIEFS Dec 5, 2005
Fort Worth Star Telegram, Promising new research finds that the leukemia drug Gleevec -- imatinib mesylate -- could one day help shield people from smallpox, a virus that experts fear ...
|
|
